Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):1005–1008. doi: 10.1128/aac.40.4.1005

Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children.

L Pacifico 1, F Scopetti 1, A Ranucci 1, M Pataracchia 1, F Savignoni 1, C Chiesa 1
PMCID: PMC163247  PMID: 8849215

Abstract

The efficacy and safety of a 3-day course of azithromycin oral suspension (10 mg/kg of body weight once daily) were compared with those of penicillin V (50,000 U/kg/day in two divided doses) in children aged 3 to 12 years for the treatment of symptomatic pharyngitis caused by the group A beta-hemolytic streptococcus (GABHS). For the 154 evaluable patients, the original infecting strain of GABHS was eliminated at the end of follow-up (34 to 36 days after treatment started) from 67 (85.8%) of 78 penicillin-treated patients and 41 (53.9%) of 76 azithromycin-treated patients (P < 0.0001). Overall clinical success was achieved in 71 (91.0%) of 78 penicillin V-treated patients and 57 (75.0%) of 76 azithromycin-treated patients (P < 0.05). Potential drug-related adverse events were reported for 5.5 and 8.6% of the penicillin V- and azithromycin-treated patients, respectively (P = 0.6). In the present study, a once-daily (10 mg/kg), 3-day oral regimen of azithromycin was as safe as a 10-day course of penicillin but did not represent an effective alternative to penicillin for the treatment of GABHS pharyngitis, even for those children with azithromycin-susceptible strains.

Full Text

The Full Text of this article is available as a PDF (174.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aujard Y., Boucot I., Brahimi N., Chiche D., Bingen E. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J. 1995 Apr;14(4):295–300. doi: 10.1097/00006454-199504000-00009. [DOI] [PubMed] [Google Scholar]
  2. BERNSTEIN S. H., FELDMAN H. A., HARPER O. F., Jr, KLINGENSMITH W. H., CANTOR J. A. Observations in air force recruits of streptococcal diseases and their control with orally administered penicillin. J Lab Clin Med. 1954 Jul;44(1):1–13. [PubMed] [Google Scholar]
  3. Borzani M., Varotto F., Garlaschi L., Conio F., Dell'Olio M., Careddu P. Clinical and microbiological evaluation of miocamycin activity against group A beta-hemolytic streptococci in pediatric patients. Three years' incidence of erythromycin-resistant group A streptococci. J Chemother. 1989 Feb;1(1):35–38. doi: 10.1080/1120009x.1989.11738861. [DOI] [PubMed] [Google Scholar]
  4. Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis. 1984 Sep-Oct;6(5):601–607. doi: 10.1093/clinids/6.5.601. [DOI] [PubMed] [Google Scholar]
  5. Chiesa C., Pacifico L., Nanni F., Ravagnan G. Evaluation of culture techniques for GABHS. Am J Clin Pathol. 1992 Jan;97(1):157–158. doi: 10.1093/ajcp/97.1.157. [DOI] [PubMed] [Google Scholar]
  6. Danjani A. S., Bisno A. L., Chung K. J., Durack D. T., Gerber M. A., Kaplan E. L., Millard H. D., Randolph M. F., Shulman S. T., Watanakunakorn C. Prevention of rheumatic fever. A statement for health professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation. 1988 Oct;78(4):1082–1086. doi: 10.1161/01.cir.78.4.1082. [DOI] [PubMed] [Google Scholar]
  7. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  8. Gerber M. A., Randolph M. F., Chanatry J., Wright L. L., De Meo K., Kaplan E. L. Five vs ten days of penicillin V therapy for streptococcal pharyngitis. Am J Dis Child. 1987 Feb;141(2):224–227. doi: 10.1001/archpedi.1987.04460020114043. [DOI] [PubMed] [Google Scholar]
  9. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother. 1993 Jun;31 (Suppl E):89–94. doi: 10.1093/jac/31.suppl_e.89. [DOI] [PubMed] [Google Scholar]
  10. Kim K. S., Kaplan E. L. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr. 1985 Nov;107(5):681–684. doi: 10.1016/s0022-3476(85)80392-9. [DOI] [PubMed] [Google Scholar]
  11. Markowitz M., Gerber M. A., Kaplan E. L. Treatment of streptococcal pharyngotonsillitis: reports of penicillin's demise are premature. J Pediatr. 1993 Nov;123(5):679–685. doi: 10.1016/s0022-3476(05)80840-6. [DOI] [PubMed] [Google Scholar]
  12. Pacifico L., Mancuso G., Properzi E., Ravagnan G., Pasquino A. M., Chiesa C. Comparison of nephelometric and hemolytic techniques for determination of antistreptolysin O antibodies. Am J Clin Pathol. 1995 Apr;103(4):396–399. doi: 10.1093/ajcp/103.4.396. [DOI] [PubMed] [Google Scholar]
  13. Pichichero M. E. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J. 1993 Apr;12(4):268–274. doi: 10.1097/00006454-199304000-00002. [DOI] [PubMed] [Google Scholar]
  14. Schwartz R. H., Wientzen R. L., Jr, Pedreira F., Feroli E. J., Mella G. W., Guandolo V. L. Penicillin V for group A streptococcal pharyngotonsillitis. A randomized trial of seven vs ten days' therapy. JAMA. 1981 Oct 16;246(16):1790–1795. doi: 10.1001/jama.246.16.1790. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES